## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.0% in mid entry zone (3.0-6.0%), top quartile (87th pct) cross-sectional ranking. Short-term MRS_5 (2.7%) confirms momentum alignment. Strong momentum (+2.9% 5-day acceleration). Outperforming sector by 7.3%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($181.73)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Charles River Laboratories International, Inc. $CRL Shares Acquired by Bank of Nova Scotia**
- Source: MarketBeat | 20251209T085506 | Bullish | Relevance: 98%
-  Bank of Nova Scotia significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by 10,860.5% in the second quarter, acquiring an additional 201,463 shares to hold a total of 203,318 shares. Other institutional investors like Burgundy Asset Management, Federated Hermes, and Amundi also made substantial purchases, bringing the total institutional ownership to 98.91% of the company's stock. Analysts currently rate CRL as a "Moderate Buy" with an average price target of $190.86, despite mixed fundamentals including a negative net margin.

**2. Charles River (NYSE: CRL) names 6 firms to cell & gene therapy incubator, opens 2026 apps**
- Source: Stock Titan | 20251211T130149 | Bullish | Relevance: 98%
- Charles River Laboratories International, Inc. (NYSE: CRL) has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP), selecting six companies focused on advanced therapy development and enabling technologies. The program aims to accelerate the development of life-changing therapies by providing scientific and commercial expertise, regulatory guidance, and access to Charles River's global network and manufacturing capabilities. Applications for the 2026 cohort are now open, continuing Charles River's commitment to supporting early-stage biotechnology innovators.

**3. Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort**
- Source: Business Wire | 20251211T130801 | Bullish | Relevance: 97%
- Charles River Laboratories International, Inc. (NYSE: CRL) has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). This program offers early-stage biotechnology companies access to Charles River's scientific expertise, development capabilities, and manufacturing resources to accelerate advanced therapy development. The cohort includes four advanced therapy developers and two enabling technology developers, benefiting from tailored mentorship, regulatory expertise, and facility access, aiming to transform innovative ideas into impactful treatments.

**4. Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort**
- Source: PharmiWeb.com | 20251211T160554 | Bullish | Relevance: 97%
-  Charles River Laboratories announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP), supporting early-stage biotechnology with scientific expertise and development capabilities. The program features four advanced therapy developers and two enabling technology developers, aiming to accelerate the creation of life-changing therapies. Participants receive mentorship, regulatory guidance, and access to Charles Riverâ€™s global network to advance their programs from concept to cure.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 17.8x stretched relative to 7% growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.6B |
| Beta | 1.64 |
| 52W Range | $91.86 - $199.66 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 17.8 |
| Current P/E | 19.0 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.1% to 5.0% (+2.9% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 87th percentile. MRS_5 at 2.7% confirms short-term momentum alignment. Outperforming sector by 7.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.25), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.99% (CS: 88) | Strong |
| RSI_14 | 69.8 | Neutral |
| MACD Histogram | 2.25 | Bullish |
| vs SMA20 | 1.103x | Above |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 1.243x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $194.43
- **Stop Loss:** $181.73 (6.5% risk)
- **Target:** $213.48 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 108
- **Position Value:** $20,998.44
- **Portfolio %:** 21.00%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*